Is There Room for Personalized Medicine in Small-Cell Lung Cancer (SCLC)? Remarkable Activity of Pazopanib in Refractory FGFR1-Amplified ED-SCLC

JCO Precis Oncol. 2019 Dec:3:1-8. doi: 10.1200/PO.19.00243.

Authors

Alessandro Russo^{1

2}, David Arias Ron³, Marika Rasschaert³, Hans Prenen³, Ranee Mehra¹, Katherine Scilla¹, Patrick Pauwels³, Christian Rolfo^{1

3}

Affiliations

¹ University of Maryland Medical Center Greenebaum Comprehensive Cancer Center, Baltimore, MD.
² A.O. Papardo and University of Messina, Messina, Italy.
³ University Hospital Antwerp, Antwerp University, Antwerp, Belgium.

PMID: 35100736
DOI: 10.1200/PO.19.00243

No abstract available